Complementary to the results described above in RPTC-CB1−/− mice, chronic treatment with SLV-319 (3 mg/kg, orally for 16 weeks), a globally acting CB1R blocker, attenuated the bone loss in an STZ-induced T1D model (Figure 4) without affecting either body weight or systemic glucose homeostasis (Figure S5). The gene discussed is CNR1; the disease is type 1 diabetes mellitus.